AGM Statement

Alliance Pharma PLC
16 May 2007


For immediate release                                           16 May 2007





                              ALLIANCE PHARMA PLC

                         ('Alliance' or 'the Company')



                                 AGM Statement





Alliance Pharma plc (AIM: APH), the emerging speciality pharmaceutical company,
will hold its Annual General Meeting in London this morning.



Michael Gatenby, the Company's Chairman, will make the following comments:



'In our 2006 preliminary results we noted that the phasing of profit in 2007
would be affected by the timing of production transfers of recently acquired
brands. Since then we have had to switch the supplier of the Atarax active
ingredient following a fire at the previous supplier. Overall demand for our
products is satisfactory. However temporary supply shortfalls will adversely
affect our first half results. The steps taken to address these issues, and
further management action, is expected to restore profitability in the second
half to deliver a full year's trading result in excess of last year's.



'Discussions with potential partners for the next stages of development and then
the marketing of Posidorm are on-going and, pending their outcome, we are
incurring no further development costs. The status of Isprelor remains that
Phase III trials have been completed, the results are expected shortly and
partnership discussions are on-going.



'I am pleased to report that following the recent acquisition of the marketing
rights to Forceval in China the initial shipments of the product have been
despatched.'





For further information:


Alliance Pharma plc                                         + 44 (0) 1249 466966
John Dawson, Chief Executive
www.alliancepharma.co.uk

Buchanan Communications                                    + 44 (0) 20 7466 5000
Mark Court/Rebecca Skye Dietrich




Notes to editors

About Alliance Pharma

Alliance Pharma, founded in 1996, is an AIM listed emerging speciality
pharmaceutical company based in Chippenham, Wiltshire, UK. The company has a
strong track record of acquiring the rights to established niche brands and
owns, or shares, the rights to 34 branded pharmaceutical products.



Alliance Pharma's products are prescribed in the treatment of a wide range of
conditions and include brands used in periodontitis (a serious gum disease), the
prevention of heart disease, in Parkinson's disease, in nutrition, in nasal
infections, in the treatment of dermatological conditions and in childbirth.
Alliance Pharma's sales are mainly prescription driven.  Its products are
distributed to hospitals directly and to pharmaceutical wholesalers which
service both hospital and retail pharmacies with their prescription
requirements.



Alliance Pharma joined the AIM market of the London Stock Exchange in December
2003 and trades under the symbol APH.




                      This information is provided by RNS
            The company news service from the London Stock Exchange